Brief: Aim Immunotech Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors
18/03/2026 12:37
March 18 (Reuters) - AIM ImmunoTech Inc AIM.A: AIM IMMUNOTECH ANNOUNCES FINAL APPROVAL OF NOVEL CANCER THERAPY PATENT IN JAPAN COMBINING AMPLIGEN WITH CHECKPOINT INHIBITORS AIM IMMUNOTECH INC - JAPAN PATENT GRANTED IN SEPTEMBER 2025 AFTER 6-MONTH OPPOSITION PERIOD AIM IMMUNOTECH INC - JAPAN PATENT EXPIRES DECEMBER 20, 2039 AIM IMMUNOTECH INC - TO PURSUE ORPHAN DRUG DESIGNATION IN JAPAN FOR AMPLIGEN IN PANCREATIC CANCER Source text: ID:nGNX4t6FKB Further company coverage: AIM.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential